All In Biotech

Drug Trial Radar · NCT00060515

RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease

An Open-Label Dose-Escalation Phase I Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RG2133 (2',3',5'-Tri-O-Acetyluridine) in the Treatment of Inherited Mitochondrial Diseases

Last checked: Nov 20, 2026Latest source record: Aug 5, 2005 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

12

Actual

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Repligen CorporationIndustry
Sponsor type
Industry
First posted
May 8, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Primary purpose
Treatment
Who can join
All sexes, from 3 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.

Conditions

  • Mitochondrial Diseases

Interventions

  • RG2133 (2',3',5'-tri-O-acetyluridine)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.